Although evidences suggest that blocking TGFβ would be beneficial for NASH, targeting TGFβ at the receptor level is probably not recommendable considering the multi-functional role of TGFβ. This evidence concerns the gene TGFB1 and metabolic dysfunction-associated steatohepatitis.